drugset / Trial / NCT03398083
Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam
RandomizedCrossoverTriple-blindDiagnostic
Summary
The purpose of this study is to evaluate the abuse potential of CBD to determine whether it should remain as a Schedule I drug under the Controlled Substances Act, or be recommended for decontrol.
Timeline
- Start
- 2017-12-04
- Primary completion
- 2018-05-30
- Completion
- 2018-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alprazolam | Small molecule | 1.5 mg | Oral |
| Comparator | CBD | Unknown | 500 mg | Oral |
| Comparator | CBD | Unknown | 1000 mg | Oral |
| Comparator | THC | Unknown | 2.5 mg | Oral |
| Comparator | THC | Unknown | 30 mg | Oral |